Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • News
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • News
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. NATtrol Controls
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

NATtrol Controls

[0661-C7592-100] Chemistry Controls 1 & 2 (for monitoring precision in the quantitative determination of multiple analytes in serum) - Set 20x5mL
Chemistry Controls 1 & 2 (for monitoring precision in the quantitative determination of multiple analytes in serum) - Set 20x5mL
312.00 € 312.0 EUR
[0500-CMV-Null-RB-PBS] CMV Control Lentivector, RFP-Bsd, x10^7
CMV Control Lentivector, RFP-Bsd, x10^7
978.00 € 978.0 EUR
[0500-CMV-Null-RB] CMV Control  lentiviral Particle (RFP-Bsd), 1 x107 IFU/ml x 200ul
CMV Control lentiviral Particle (RFP-Bsd), 1 x107 IFU/ml x 200ul
365.00 € 365.0 EUR
[0868-M420] BioFire® JI Control Panel M420  12 tubes x 200 µL; 6 x Positive, 6 x Negative Controls
BioFire® JI Control Panel M420 12 tubes x 200 µL; 6 x Positive, 6 x Negative Controls
935.00 € 935.0 EUR
[0868-M441] BioFire RP2.1/RP2.1plus Control Panel M441 (includes M441 SARS-CoV-2) , 12 x 300 µL
BioFire RP2.1/RP2.1plus Control Panel M441 (includes M441 SARS-CoV-2) , 12 x 300 µL
940.00 € 940.0 EUR
[0868-M262] BioFire ME Control Panel, 12 tubes x 200µւ
BioFire ME Control Panel, 12 tubes x 200µւ
923.00 € 923.0 EUR
[0556-N15-MBC069] Amplirun® West Nile Virus RNA Control 12,000-20,000 c/µl
Amplirun® West Nile Virus RNA Control 12,000-20,000 c/µl
667.00 € 667.0 EUR
[0556-N15-MBTC024-R] Amplirun® Total CT/NG/TV/mG.E Control (Swab)
Amplirun® Total CT/NG/TV/mG.E Control (Swab)
556.50 € 556.5 EUR
[0556-N15-MBTC006] Amplirun® Total CT/NG Control (Exudate)
Amplirun® Total CT/NG Control (Exudate)
482.00 € 482.0 EUR
[0556-N15-MBTC018-R] Amplirun® Total CMV Control (Plasma)
Amplirun® Total CMV Control (Plasma)
343.00 € 343.0 EUR
[0556-N15-MBC137] Amplirun® SARS-CoV-2 RNA Control - 12,500-20,000 c/μl
Amplirun® SARS-CoV-2 RNA Control - 12,500-20,000 c/μl
694.00 € 694.0 EUR
[0556-N15-MBC102] Amplirun® Parechovirus Virus RNA Control 12,500-20,000 c/µl
Amplirun® Parechovirus Virus RNA Control 12,500-20,000 c/µl
688.50 € 688.5 EUR
[0556-N15-MBC014] Amplirun® Coccidioides Immitis DNA Control 10,000-20,000 c/µl
Amplirun® Coccidioides Immitis DNA Control 10,000-20,000 c/µl
667.00 € 667.0 EUR
[0556-N15-MBC076] Amplirun® Borrelia Burgdorferi DNA Control, 10,000-20,000 c/µl
Amplirun® Borrelia Burgdorferi DNA Control, 10,000-20,000 c/µl
689.00 € 689.0 EUR
[0556-N15-MBC004] Amplirun® Bacillus Cereus DNA Control 10,000-20,000 c/µl
Amplirun® Bacillus Cereus DNA Control 10,000-20,000 c/µl
693.00 € 693.0 EUR
[0556-MBC002-R] Amplirun® Aspergillus Fumigatus DNA Control - 10,000-20,000 c/µl
Amplirun® Aspergillus Fumigatus DNA Control - 10,000-20,000 c/µl
688.50 € 688.5 EUR
[0556-N15-MBC068] Amplirun Papillomavirus Type 18 DNA Control
Amplirun Papillomavirus Type 18 DNA Control
639.00 € 639.0 EUR
[0556-N15-MBC067] Amplirun Papillomavirus Type 16 DNA Control
Amplirun Papillomavirus Type 16 DNA Control
639.00 € 639.0 EUR
[0002-KZMC035] Adenovirus Rapid Test Control Pack - 2 X 1.5mL
Adenovirus Rapid Test Control Pack - 2 X 1.5mL
371.00 € 371.0 EUR
[0556-MBC118-R] AMPLIRUN® Vibrio Cholerae DNA Control
AMPLIRUN® Vibrio Cholerae DNA Control
628.50 € 628.5 EUR
  • 1
  • 2
  • 3
  • 4
  • 5

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)